Immunohistochemical evidence for the over-expression of Glutathione peroxidase 3 in clear cell type ovarian adenocarcinoma
- PMID: 20730571
- DOI: 10.1007/s12032-010-9659-0
Immunohistochemical evidence for the over-expression of Glutathione peroxidase 3 in clear cell type ovarian adenocarcinoma
Abstract
Glutathione peroxidase 3 (GPX3) is a member of glutathione peroxidase family, exerting one of the most important cellular defense mechanisms against stress signals, including oxidative damage. In this study, the expression of GPX3 mRNA and protein was analyzed for ovarian cancer tissues to test its applicability as a biomarker that can distinguish the four major histologic types of epithelial ovarian cancer. A public microarray dataset containing 99 ovarian cancer and 4 normal ovary samples was downloaded, and GPX3 mRNA expression was analyzed. The expression of GPX3 protein was measured by immunohistochemical staining in 40 epithelial ovarian cancer tissues, 10 for each of the serous, endometrioid, mucinous, and clear cell type. Histoscores were made from the immunohistostaining, and analysis of variance (ANOVA) was performed to quantitate the differences in protein level. Analysis of genomic dataset confirms a GPX3 overexpression in clear cell type ovarian adenocarcinoma compared with normal ovary and 3 other subtypes of epithelial ovarian cancer at mRNA level. GPX3 also shows the highest average antibody staining intensities in clear cell type ovarian adenocarcinomas over the other 3 types in immunostaining on tissue arrays. This is the first validation of GPX3 as a clear cell type-specific biomarker in ovarian cancer patients' tissues by immunostaining. GPX3 may serve as an important molecular marker for the diagnosis and molecular understanding of clear cell carcinoma of the ovary.
Similar articles
-
Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma.Oncol Rep. 2008 Dec;20(6):1299-303. Oncol Rep. 2008. PMID: 19020706
-
GPx3 supports ovarian cancer progression by manipulating the extracellular redox environment.Redox Biol. 2019 Jul;25:101051. doi: 10.1016/j.redox.2018.11.009. Epub 2018 Nov 17. Redox Biol. 2019. PMID: 30509602 Free PMC article.
-
Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.Clin Cancer Res. 2005 Sep 15;11(18):6422-30. doi: 10.1158/1078-0432.CCR-05-0508. Clin Cancer Res. 2005. PMID: 16166416
-
[Gene expression profiling of human ovarian epithelial tumors by digo nucleotide microarray].Hum Cell. 2001 Dec;14(4):261-6. Hum Cell. 2001. PMID: 11925926 Review. Japanese.
-
Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7. Pathology. 2011. PMID: 21716157 Review.
Cited by
-
CancerMA: a web-based tool for automatic meta-analysis of public cancer microarray data.Database (Oxford). 2012 Dec 15;2012:bas055. doi: 10.1093/database/bas055. Print 2012. Database (Oxford). 2012. PMID: 23241162 Free PMC article.
-
Advances in the role of GPX3 in ovarian cancer (Review).Int J Oncol. 2024 Mar;64(3):31. doi: 10.3892/ijo.2024.5619. Epub 2024 Feb 1. Int J Oncol. 2024. PMID: 38299269 Free PMC article.
-
Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression.J Ovarian Res. 2011 Oct 22;4:18. doi: 10.1186/1757-2215-4-18. J Ovarian Res. 2011. PMID: 22017790 Free PMC article.
-
GPX3 supports ovarian cancer tumor progression in vivo and promotes expression of GDF15.Gynecol Oncol. 2024 Jun;185:8-16. doi: 10.1016/j.ygyno.2024.02.004. Epub 2024 Feb 10. Gynecol Oncol. 2024. PMID: 38342006 Free PMC article.
-
Selenium, Selenoproteins, and Female Reproduction: A Review.Molecules. 2018 Nov 22;23(12):3053. doi: 10.3390/molecules23123053. Molecules. 2018. PMID: 30469536 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous